Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-like peptides
Relations of insulin sensitivity to longitudinal blood pressure tracking: variations with baseline age, body mass index, and blood pressure
Liraglutide doses similarly increased mean postprandial satiety and fullness ratings, reduced hunger and prospective food consumption and decreased ad libitum energy intake by 16%
The development of oral glucagon like peptide 1 analogs offers a transformative opportunity to enhance patient convenience, improve compliance, and expand the target demographic, particularly among individuals with needle aversions or injection phobia
Remember, your health and well-being are paramount
These pressures, alongside a frequent lack of practitioner education about integrating lifestyle management in medicine, have created a dearth of implemented behavioral and lifestyle counseling, accessible and effective referral programs, and integration into existing care delivery systems